|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation显示文摘Several therapeutic procedures have been proposed as bridging treatments for patients with hepatocellular carcinoma(HCC)awaiting liver transplantation(LT).The most used treatments include transarterial chemoembolization and radiofrequency ablation.Surgical resection has also been successfully used as a bridging procedure,and LT should be considered a rescue treatment in patients with previous HCC resection who experience tumor recurrence or post-treatment severe decompensation of liver function.The aims of bridging treatments include decreasing the waiting list dropout rate before transplantation,reducing HCC recurrence after transplantation,and improving post-transplant overall survival.To date,no data from prospective randomized studies are available;however,for HCC patients listed for LT within the Milan criteria,prolonging the waiting time over 6-12 mo is a risk factor for tumor spread.Bridging treatments are useful in containing tumor progression and decreasing dropout.Furthermore,the response to pre-LT treatments may represent a surrogate marker of tumor biological aggressiveness and could therefore be evaluated to prioritize HCC candidates for LT.Lastly,although a definitive conclusion can not be reached,the experiences reported to date suggest a positive impact of these treatments on both tumor recurrence and post-transplant patient survival.Advanced HCC may be downstaged to achieve and maintain the current conventional criteria for inclusion in the waiting list for LT.Recent studies have demonstrated that successfully downstaged patients can achieve a 5-year survival rate comparable to that of patients meeting the conventional criteria without requiring downstaging. | Maurizio Pompili Giampiero Francica Francesca Romana Ponziani Roberto Iezzi Alfonso Wolfango Avolio | 2013 | World Journal of Gastroenterology2013，19，43： | 24 |
| 2 | Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers显示文摘Hepatocellular carcinoma is one of the most frequent malignant tumors worldwide:Portal vein tumor thrombosis(PVTT)occurs in about 35%-50%of patients and represents a strong negative prognostic factor,due to the increased risk of tumor spread into the bloodstream,leading to a high recurrence risk.For this reason,it is a contraindication to liver transplantation and in several prognostic scores sorafenib represents its standard of care,due to its antiangiogenetic action,although it can grant only a poor prolongation of life expectancy.Recent scientific evidences lead to consider PVTT as a complex anatomical and clinical condition,including a wide range of patients with different prognosis and new treatment possibilities according to the degree of portal system involvement,tumor biological aggressiveness,complications caused by portal hypertension,patient’s clinical features and tolerance to antineoplastic treatments.The median survival has been reported to range between 2.7 and 4 mo in absence of therapy,but it can vary from 5 mo to 5 years,thus depicting an extremely variable scenario.For this reason,it is extremely important to focus on the most adequate strategy to be applied to each group of PVTT patients. | Lucia Cerrito Brigida Eleonora Annicchiarico Roberto Iezzi Antonio Gasbarrini Maurizio Pompili Francesca Romana Ponziani | 2019 | World Journal of Gastroenterology2019，25，31： | 21 |
| 3 | Combined locoregional treatment of patients withhepatocellular carcinoma: state of the art显示文摘In recent years, a combination of intervention therapies has been widely applied in the treatment of hepatocellular carcinoma(HCC). One such combined strategy is based on the combination of the percutaneous approach, such as radiofrequency ablation(RFA), and the intra-arterial locoregional approach, such as trans-arterial chemoembolization(TACE). Several types of evidence have supported the feasibility and benefit of combined therapy, despite some studies reporting conflicting results and outcomes. The aim of this review was to explain the technical aspects of different combined treatments and to comprehensively analyze and compare the clinical efficacy and safety of this combined treatment option and monotherapy, either as TACE or RFA alone, in order to provide clinicians with an unbiased opinion and valuable information. Based on a literature review and our experience, combined treatment seems to be a safe and effective option in the treatment of patients with early/intermediate HCC when surgical resection is not feasible; furthermore, this approach provides better results than RFA and TACE alone for the treatment of large HCC, defined as those exceeding 3 cm in size. It can also expand the indication for RFA to previously contraindicated 'complex cases', with increased risk of thermal ablation related complications due to tumor location, or to 'complex patients' with high bleeding risk. | Roberto Iezzi Maurizio Pompili Alessandro Posa Giuseppe Coppola Antonio Gasbarrini Lorenzo Bonomo | 2016 | World Journal of Gastroenterology2016，22，6： | 15 |
| 4 | Contemporary Chinese Calligraphy Between Tradition and Innovation显示文摘 | Adriana Iezzi | 2013 | Journal of Literature and Art Studies2013，3，3： | 2 |
| 5 | Electroporated DNA vaccine clears away muhifocal mammary carcinomas in her- 2/neu transgenic mice 显示文摘 | Quaglino E Iezzi M Mastini C | 2004 | Cancer Res2004，64，8： | 1 |
| 6 | Bone rereneration with calcium sulfate :Evidence for increased angiogenesis in rabbits显示文摘 | Strocchi MD Ovanna Orsini ovanna Iezzi DDS | 2002 | Journal of oral implantology2002，28，6： | 1 |
| 7 | Optimal cut-offs for Down syndrome contingent screening in a population of 10,156 pregnant women显示文摘 | Guanciali-Franchi P Iezzi I Soranno A | 2012 | Prenat Diagn2012，32，12： | 1 |
| 8 | COX-2:friend or foe? 显示文摘 | IEZZI A FERRI C MEZZETTI A | 2007 | Curt Pharm Des2007，13，16： | 1 |
| 9 | Contemporary immunotherapy of solid tumors : From tumor-associated antigens to combination treatment 显示文摘 | Spagnoli GC Ebrahimi M Iezzi G Mengus C Zajac P | 2010 | Curr Opin Drug Discov Devel2010，13，2： | 1 |
| 10 | Hybrid therapy in patients with complex peripheral multifocal steno-obstructive vascular disease:two-year results显示文摘 | Cotroneo AR Iezzi R Marano G | 2007 | Cardiovasc Intervent Radiol2007，30，3： | 1 |
| 11 | No face-down positioning and broad internal limiting membrane peeling in the surgical repair of idiopathic macular holes 显示文摘 | Iezzi R Kapoor KG | 2013 | Ophthalmology2013，120，： | 1 |
| 12 | Foot CT perfusion in pa- tients with peripheral arterial occlusive disease (PAOD) : a feasi- bility study显示文摘 | Iezzi R Santoro M Dattesi R | 2013 | Eur J Radiol2013，82，9： | 1 |
| 13 | Plagioclase-melt(dis)equilibrium due to cooling dynamics:implications for thermometry,barometry and hygrometry显示文摘 | Mollo S Putirka K Iezzi G | 2011 | Lithos2011，125，： | 1 |
| 14 | facedown positioning is not necessary in idiopathic macular hole repair 显示文摘 | Iezzi R | 2014 | Retina Today2014，，2： | 1 |
| 15 | A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma显示文摘 | Johannes Haybaeck Nicolas Zeller Monika Julia Wolf Achim Weber Ulrich Wagner Michael Odo Kurrer Juliane Bremer Giandomenica Iezzi Rolf Graf Pierre-Alain Clavien Robert Thimme Hubert Blum Sergei A. Nedospasov Kurt Zatloukal Muhammad Ramzan Sandra Ciesek Th | 2009 | Cancer Cell2009，，4： | 1 |
| 16 | Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice显示文摘 | Quaglino E Iezzi M Mastini C | 2004 | Cancer Res2004，64，8： | 1 |
| 17 | Implant surface topographies analyzed using fractal dimension显示文摘 | Iezzi G Aprile G Tripodi D | | 0，，02： | 1 |
| 18 | Low-dose muhidetector CT angiography in the evaluation of infrarenal aorta and peripheral arterial occlusive disease显示文摘 | Iezzi R Santoro M Marano R | 2012 | Radiology2012，263，： | 1 |
| 19 | The receptor RAGE as a progression factor amplifying arachidonate-dependent infiammatory and proteolytic response in human athemselerotie plaques:role of glycemic control显示文摘 | CIPOLLONE F IEZZI A FAZIA M | 2003 | Circulation2003，108，9： | 1 |
| 20 | Blockade of the angiotensin Ⅱ type 1 receptor stabilizes atherosclerotic plaques in humans by inhibi- ting prostaglandin E-dependent matrix metalloproteinase activity显示文摘 | Cipollone F Fazia M Iezzi A | 2004 | Circulation2004，30，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员